187 related articles for article (PubMed ID: 30224328)
1. Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Papasotiriou I; Fotiou D; Migkou M; Roussou M; Kanellias N; Ziogas D; Dialoupi I; Eleutherakis Papaiakovou E; Kastritis E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):23-28. PubMed ID: 30224328
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia.
Hivert B; Caron C; Petit S; Charpy C; Fankam-Siaka C; Lecocq S; Zawadzki C; Susen S; Rusu M; Duhamel A; Tournilhac O; Goudemand J; Morel P
Blood; 2012 Oct; 120(16):3214-21. PubMed ID: 22896002
[TBL] [Abstract][Full Text] [Related]
3. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
Vitolo U; Ferreri AJ; Montoto S
Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis.
Kastritis E; Papassotiriou I; Terpos E; Roussou M; Gavriatopoulou M; Komitopoulou A; Skevaki C; Eleutherakis-Papaiakovou E; Pamboucas C; Psimenou E; Manios E; Giannouli S; Politou M; Gakiopoulou H; Papadopoulou E; Stamatelopoulos K; Tasidou A; Dimopoulos MA
Blood; 2016 Jul; 128(3):405-9. PubMed ID: 27166361
[TBL] [Abstract][Full Text] [Related]
5. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.
Jalali S; Ansell SM
Best Pract Res Clin Haematol; 2016 Jun; 29(2):148-155. PubMed ID: 27825460
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.
Kyle RA; Ansell SM; Kapoor P
Best Pract Res Clin Haematol; 2016 Jun; 29(2):179-186. PubMed ID: 27825464
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
9. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422
[TBL] [Abstract][Full Text] [Related]
10. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
Jalali S; Ansell SM
Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.
Al-Awadhi A; Adekile A; Marouf R
J Thromb Thrombolysis; 2017 Jan; 43(1):117-123. PubMed ID: 27613177
[TBL] [Abstract][Full Text] [Related]
12. Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.
Merchionne F; Procaccio P; Dammacco F
Crit Rev Oncol Hematol; 2011 Oct; 80(1):87-99. PubMed ID: 21036057
[TBL] [Abstract][Full Text] [Related]
13. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure.
Martin K; Borgel D; Lerolle N; Feys HB; Trinquart L; Vanhoorelbeke K; Deckmyn H; Legendre P; Diehl JL; Baruch D
Crit Care Med; 2007 Oct; 35(10):2375-82. PubMed ID: 17944029
[TBL] [Abstract][Full Text] [Related]
14. Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients.
Karakaya B; Tombak A; Serin MS; Tiftik N
Hematology; 2016 Jun; 21(5):295-9. PubMed ID: 26872106
[TBL] [Abstract][Full Text] [Related]
15. Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study.
Castelli R; Bergamaschini L; Teatini T; Cilumbriello L; Schiavon R; Gallipoli P; Deliliers GL
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e461-e467. PubMed ID: 32507387
[TBL] [Abstract][Full Text] [Related]
16. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
Ward SE; Fogarty H; Karampini E; Lavin M; Schneppenheim S; Dittmer R; Morrin H; Glavey S; Ni Cheallaigh C; Bergin C; Martin-Loeches I; Mallon PW; Curley GF; Baker RI; Budde U; O'Sullivan JM; O'Donnell JS;
J Thromb Haemost; 2021 Aug; 19(8):1914-1921. PubMed ID: 34053187
[TBL] [Abstract][Full Text] [Related]
17. Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity.
Al-Awadhi A; Adekile A; Marouf R
Acta Haematol; 2021; 144(2):182-189. PubMed ID: 32987383
[TBL] [Abstract][Full Text] [Related]
18. [Application Value of Plasma vWF and ADAMTS-13 in Evaluating Postoprative Vascular Endothelial Injury and Prognosis in Children with VSD].
Wang XY; Zhang QW; Shen YM; Liu JF; Li WZ; Jia KG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):189-196. PubMed ID: 36765498
[TBL] [Abstract][Full Text] [Related]
19. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.
Guo R; Yang J; Liu X; Wu J; Chen Y
J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28374895
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting transformation of asymptomatic IgM monoclonal gammopathy.
Greco A; Tedeschi A; Varettoni M; Nichelatti M; Paris L; Ricci F; Vismara E; Morra E
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):77-9. PubMed ID: 21454196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
